Fosun Pharmaceutical, a leading healthcare group, has taken a substantial step towards introducing particle therapy systems to hospitals in mainland China, aligning with Beijing’s efforts to make advanced medical treatment accessible to cancer patients across the country. The Shanghai-based company, a subsidiary of China’s non-state-owned conglomerate Fosun International, formed a partnership with Leo Cancer Care on Thursday, pledging to distribute the UK firm’s Marie medical facilities in the...